Venlafaxine for Hot Flashes After Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

The purpose of this study is to evaluate Venlafaxine as a treatment option for hot flashes in breast cancer survivors. The goals of this study are to assess the effectiveness and toxicity of venlafaxine hydrochloride and identify the psychological, behavioral, and physical outcomes associated with relief of hot flashes in women following treatment for breast cancer.

Key facts

Study ID: NCT00198250
Run by: Indiana University
People needed: 75
Starts: 2000-05-01
Expected to finish: 2005-11-01
Last updated by the study team: 2008-11-14

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

women at least 21 years of age
willing and able to provide informed consent
first time diagnosis of breast cancer
no other history of cancer
considered disease free at time of study enrollment
at least four weeks post-completion of surgery, radiation, and/or chemotherapy for non-metastatic cancer
experiencing daily hot flashes
desirous of treatment for hot flashes, but not concurrently using any other hot flash treatments
living within 60 miles of Indianapolis
able to read, write and speak English

You may not qualify if…

current treatment with antidepressants for depression, neuropathic pain or hot flashes
diagnosis of metastatic breast cancer (stage IV)
treatment for hot flashes within the past four weeks, including (a) soy supplements; (b) botanicals, such as dong quai (Angelica sinensis), black cohosh, ginseng, gotu kola, licorice root, chaste tree, sage, or wild yam root; (c) vitamin E; or (d) prescription medications, such as clonidine hydrochloride or megestrol acetate.

Where it is running

Indiana University Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.